Clinical characteristics of functioning gonadotroph adenoma in women presenting with ovarian hyperstimulation: Audit of UK pituitary centres.
FGA
OHSS
functioning gonadotroph adenoma
ovarian hyperstimulation syndrome
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
17
05
2023
received:
13
02
2023
accepted:
03
07
2023
medline:
11
9
2023
pubmed:
11
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
Functioning gonadotroph adenomas (FGAs) are rare pituitary tumours stimulating ovarian function with potential life-threatening consequences in women. However, a lack of aggregated clinical experience of FGAs impairs management in affected women. The aim of this study is to present the clinical course of FGA-induced ovarian hyperstimulation syndrome (OHSS) cases as identified by some of the largest UK pituitary endocrine tertiary centres with a view to increasing awareness and improving diagnosis and management of women with FGA. A retrospective observational study; audit of eight UK regional pituitary centres for cases of FGAs. Specialist neuroendocrine centres in the United Kingdom. Women diagnosed with FGA-induced OHSS. Description of their clinical course. Seven cases of FGA were identified in women, all causing OHSS. Mean age was 33.4 years at diagnosis. Abdominal pain, irregular periods, headache, and visual disturbances were reported at presentation by 100%, 71%, 57% and 43% of women, respectively. Three of seven women underwent ovarian surgery before FGA diagnosis. Six women underwent transsphenoidal surgery (TSS) with incomplete tumour resection in five of those, but all showed improvement or resolution in symptoms and biochemistry postoperatively. FGA is a rare cause of spontaneous OHSS. TSS improves clinical and biochemical features of ovarian hyperstimulation in FGAs. Improved awareness of FGA will prevent inappropriate emergency ovarian surgery.
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
386-395Subventions
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
Références
Pfeifer S, Butts S, Dumesic D, et al. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106(7):1634-1647. doi:10.1016/J.FERTNSTERT.2016.08.048
Petrenko AP, Castelo-Branco C, Marshalov DV, Salov IA, Shifman EM. Ovarian hyperstimulation syndrome. A new look at an old problem. Gynecol Endocrinol. 2019;35(8):651-656. doi:10.1080/09513590.2019.1592153
Miras AD, Mogford JT, Wright J, et al. Ovarian hyperstimulation from ectopic hypersecretion of follicle stimulating hormone. Lancet. 2015;385(9965):392. doi:10.1016/S0140-6736(14)62294-7
Burgos J, Cobos P, Vidaurrazaga N, Prieto B, Ocerin I, Matorras R. Ovarian hyperstimulation secondary to ectopic secretion of follicle-stimulating hormone. Literature review prompted by a case. Fertil Steril. 2009;92(3):1168.e5-1168.e8. doi:10.1016/j.fertnstert.2009.06.023
De Leener A, Montanelli L, Van Durme J, et al. Presence and absence of Follicle-Stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J Clin Endocrinol Metab. 2006;91(2):555-562. doi:10.1210/JC.2005-1580
Panagiotopoulou N, Byers H, Newman WG, Bhatia K. Spontaneous ovarian hyperstimulation syndrome: case report, pathophysiological classification and diagnostic algorithm. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):143-148. doi:10.1016/J.EJOGRB.2013.03.004
Ntali G, Capatina C, Grossman A, Karavitaki N. Functioning gonadotroph adenomas. J Clin Endocrinol Metab. 2014;99(12):4423-4433. doi:10.1210/jc.2014-2362
Fletcher CDM. Diagnostic Histopathology of Tumors. 5th ed. Elsevier; 2020. https://www.us.elsevierhealth.com/diagnostic-histopathology-of-tumors-2-volume-set-9780323428606.html
Tashiro H, Katabuchi H, Ohtake H, Kaku T, Ushio Y, Okamura H. A follicle-stimulating hormone-secreting gonadotroph adenoma with ovarian enlargement in a 10-year-old girl. Fertil Steril. 1999;72(1):158-160. doi:10.1016/s0015-0282(99)00197-1
Faggiano M, Criscuolo T, Perrone L, Quarto C, Sinisi AA. Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma. Acta Endocrinol. 1983;102(2):167-172. doi:10.1530/acta.0.1020167
Ambrosi B, Bassetti M, Ferrario R, Medri G, Giannattasio G, Faglia G. Precocious puberty in a boy with a PRL-, LH- and FSH-secreting pituitary tumour: hormonal and immunocytochemical studies. Acta Endocrinol. 1990;122(5):569-576. doi:10.1530/ACTA.0.1220569
Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349:1614-1627.
Tena-Sempere M. The roles of kisspeptins and G protein-coupled receptor-54 in pubertal development. Curr Opin Pediatr. 2006;18(4):442-447. doi:10.1097/01.MOP.0000236396.79580.CC
Wang L, Liang H, Deng C, et al. Functioning gonadotroph adenomas in premenopausal women: clinical and molecular characterization and review of the literature. Pituitary. 2022;25(3):454-467. doi:10.1007/s11102-021-01205-9
Richard N, Galmiche G, Corvaisier S, Caraty A, Kottler ML. KiSS-1 and GPR54 genes are co-expressed in rat gonadotrophs and differentially regulatedIn vivoby oestradiol and gonadotrophin-releasing hormone. J Neuroendocrinol. 2008;20(3):381-393. doi:10.1111/J.1365-2826.2008.01653.X
Kottler ML, Seret-Bégué D, Lahlou N, et al. The GnRH receptor gene is preferentially expressed in functioning gonadotroph adenomas and displays a Mae III polymorphism site. Clin Endocrinol. 1998;49(1):115-123. doi:10.1046/J.1365-2265.1998.00500.X
Hugon-Rodin J, Sonigo C, Gompel A, et al. First mutation in the FSHR cytoplasmic tail identified in a non-pregnant woman with spontaneous ovarian hyperstimulation syndrome. BMC Med Genet. 2017;18(1):44. doi:10.1186/s12881-017-0407-6
Vasseur C, Rodien P, Beau I, et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med. 2003;349(8):753-759. doi:10.1056/NEJMoa030065
Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart G, Costagliola S. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med. 2003;349(8):760-766. doi:10.1056/NEJMoa030064
Delbaere A, Smits G, Olatunbosun O, Pierson R, Vassart G, Costagliola S. New insights into the pathophysiology of ovarian hyperstimulation syndrome. Hum Reprod. 2004;19(3):486-489. doi:10.1093/HUMREP/DEH124
Davis JRE, Mcneilly JR, Norris AJ, et al. Fetal gonadotrope cell origin of FSH-secreting pituitary adenoma-insight into human pituitary tumour pathogenesis. Clin Endocrinol. 2006;65:648-654. doi:10.1111/j.1365-2265.2006.02644.x
Hasegawa H, Nesvick CL, Erickson D, et al. Gonadotroph pituitary adenoma causing treatable infertility and ovarian hyperstimulation syndrome in female patients: neurosurgical, endocrinologic, gynecologic, and reproductive outcomes. World Neurosurg. 2021;150:e162-e175. doi:10.1016/J.WNEU.2021.02.115
Caretto A, Lanzi R, Piani C, Molgora M, Mortini P, Losa M. Ovarian hyperstimulation syndrome due to follicle-stimulating hormone-secreting pituitary adenomas. Pituitary. 2017;20(5):553-560. doi:10.1007/S11102-017-0817-7
Honigberg MC, Zekavat SM, Aragam K, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;322(24):2411-2421. doi:10.1001/jama.2019.19191
Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16(1):15-23. doi:10.1097/gme.0b013e31818888f7
Rocca WA, Lohse CM, Smith CY, Fields JA, Machulda MM, Mielke MM. Association of premenopausal bilateral oophorectomy with cognitive performance and risk of mild cognitive impairment. JAMA Netw Open. 2021;4(11):e2131448. doi:10.1001/jamanetworkopen.2021.31448
Marko J, Marko K, Pachigolla SL, Crothers B, Mattu R, Wolfman DJ. Mucinous neoplasms of the ovary: radiologic-pathologic correlation. Radiographics. 2019;39(4):982-997. doi:10.1148/rg.2019180221
Macchia E, Simoncini T, Raffaelli V, Lombardi M, Iannelli A, Martino E. A functioning FSH-secreting pituitary macroadenoma causing an ovarian hyperstimulation syndrome with multiple cysts resected and relapsed after leuprolide in a reproductive-aged woman. Gynecol Endocrinol. 2012;28(1):56-59. doi:10.3109/09513590.2011.588758
Castelbaum AJ, Bigdeli H, Post KD, Freedman MF, Snyder PJ. Exacerbation of ovarian hyperstimulation by leuprolide reveals a gonadotroph adenoma. Fertil Steril. 2002;78(6):1311-1313. doi:10.1016/S0015-0282(02)04342-X
Knoepfelmacher M, Danilovic DLS, Rosa Nasser RHR, Mendonça BB. Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. Fertil Steril. 2006;86(3):719.e15-719.e18. doi:10.1016/j.fertnstert.2006.01.055
Feldberg D, Ashkenazi J, Dicker D, Yeshaya A, Goldman GA, Goldman JA. Ovarian cyst formation: a complication of gonadotropin-releasing hormone agonist therapy. Fertil Steril. 1989;51(1):42-45. doi:10.1016/S0015-0282(16)60425-9
Lee M, Lupp A, Mendoza N, et al. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocr Relat Cancer. 2015;22(1):111-119. doi:10.1530/ERC-14-0472